TGTX
TG Therapeutics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Neutral
+18/100
Last price
52.00
▼ 1.91 (3.54%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
54.00
Prev close
53.91
Day high
54.11
Day low
51.34
Volume
2.41M
Market cap
$7.99B
P/E (TTM)
19.62
52W range
26.76 – 59.30
Day trading desk
Gap from prior close
+0.17%
Prior close 53.91
VWAP
52.20
-0.39% from price
Relative volume
2.12×
Unusually busy
Session range
6.70%
51.34 – 54.78
Position in range
19%
Near session low
ATR (14D)
2.17
4.18% of price
Prior day high
54.75
PDH
Prior day low
53.32
PDL
Bid / ask spread
—
Quote not published
Session volume
4.28M
Avg 2.02M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-7.12%
-9.1%
1M
-6.78%
-7.9%
3M
-8.81%
-13.3%
6M
+56.30%
+38.1%
YTD
+75.08%
+60.8%
1Y
+42.19%
+25.8%
3Y
+524.28%
+442.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on TGTX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+1.05K
Net buying
Buy transactions
1
6.05K shares
Sell transactions
1
5.00K shares
Net transactions
+2
Buys less sells
Sell : buy shares
0.8 : 1
Mixed
Insider-held shares
10.59M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 10, 26 | CHARNEY LAURENCE NEIL Director |
SELL | 5.00K | $274.80K | Direct |
| Aug 7, 26 | CHARNEY LAURENCE NEIL Director |
STOCK | 6.05K | $0 | Direct |
| Jan 29, 26 | CHARNEY LAURENCE NEIL Director |
STOCK | 43.20K | $0 | Direct |
| Jan 8, 26 | WEISS MICHAEL S Chief Executive Officer |
STOCK | 622.00K | $0 | Direct |
| Jan 8, 26 | POWER SEAN A Chief Financial Officer |
STOCK | 90.00K | $0 | Direct |
| Nov 24, 25 | ECHELARD YANN Director |
SELL | 5.00K | $162.85K | Direct |
| Nov 5, 25 | WEISS MICHAEL S Chief Executive Officer |
STOCK | 4.67M | $0 | Direct |
| Sep 11, 25 | LONIAL SAGAR Director |
SELL | 20.85K | $672.27K | Direct |
| Jun 13, 25 | ECHELARD YANN Director |
SELL | 10.00K | $369.40K | Direct |
| Jun 12, 25 | CHARNEY LAURENCE NEIL Director |
STOCK | 21.41K | $0 | Direct |
| Jun 12, 25 | ECHELARD YANN Director |
STOCK | 14.72K | $0 | Direct |
| Jun 12, 25 | HOBERMAN KENNETH Director |
STOCK | 14.72K | $0 | Direct |
| Jun 12, 25 | HUME DANIEL Director |
STOCK | 14.72K | $0 | Direct |
| Jun 12, 25 | LONIAL SAGAR Director |
STOCK | 14.72K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CHARNEY LAURENCE NEIL |
Director | 168.64K | Sale |
ECHELARD YANN |
Director | 223.82K | Sale |
HOBERMAN KENNETH |
Director | 279.65K | Stock Award(Grant) |
HUME DANIEL |
Director | 192.75K | Stock Award(Grant) |
LONIAL SAGAR |
Director | 94.06K | Sale |
POWER SEAN A |
Chief Financial Officer | 798.11K | Stock Award(Grant) |
WEISS MICHAEL S |
Chief Executive Officer | 9.78M | Stock Award(Grant) |
Fundamentals
Market cap$7.99B
Enterprise value$7.61B
Revenue (TTM)$799.54M
Gross profit$658.60M
EBITDA$136.45M
Net income$441.49M
EPS (TTM)$2.66
Free cash flow$59.13M
Total cash$552.25M
Total debt$754.44M
Book value / share$4.11
Shares outstanding153.08M
Float135.24M
Short % of float28.47%
Dividend yield0.00%
Beta (5Y)1.80
Valuation & profitability ratios
Trailing P/E19.62
Forward P/E19.27
PEG ratio1.61
Price / sales—
Price / book12.69
EV / revenue9.51
EV / EBITDA55.74
Gross margin82.37%
Operating margin9.02%
Profit margin55.22%
Return on equity100.28%
Return on assets7.28%
Debt / equity124.89
Current ratio4.27
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $616.29M | $329.00M | $233.66M | $2.79M | +87.3% |
| Operating revenue | $616.29M | $329.00M | $233.66M | $2.79M | +87.3% |
| Cost of revenue | $100.71M | $38.49M | $14.13M | $265.00K | +161.7% |
| Gross profit | $515.57M | $290.52M | $219.53M | $2.52M | +77.5% |
| Research & development | $160.22M | $94.29M | $76.19M | $125.35M | +69.9% |
| Selling, general & admin | $232.03M | $154.30M | $122.71M | $95.48M | +50.4% |
| Total operating expense | $392.25M | $248.59M | $198.90M | $220.84M | +57.8% |
| Operating income | $123.32M | $41.93M | $20.63M | -$218.32M | +194.1% |
| Net interest income | -$26.73M | -$24.03M | -$12.62M | -$10.19M | -11.2% |
| Pre-tax income | $107.39M | $25.59M | $13.06M | -$223.81M | +319.6% |
| Tax provision | -$339.79M | $2.21M | $390.00K | $0 | -15,468.1% |
| Net income | $447.18M | $23.38M | $12.67M | -$223.81M | +1,812.4% |
| Net income to common | $447.18M | $23.38M | $12.67M | -$223.81M | +1,812.4% |
| Basic EPS | 3.10 | 0.16 | 0.09 | -1.46 | +1,837.5% |
| Diluted EPS | 2.77 | 0.15 | 0.09 | -1.46 | +1,746.7% |
| EBIT | $134.12M | $49.62M | $25.68M | -$213.62M | +170.3% |
| EBITDA | $134.36M | $49.90M | $26.10M | -$213.11M | +169.2% |
| Basic shares | 144.32M | 145.32M | 141.96M | 135.41M | -0.7% |
| Diluted shares | 161.41M | 160.34M | 148.51M | 135.41M | +0.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $79.15M | $179.89M | $92.93M | $102.30M | — | -56.0% |
| Cash & short-term investments | $141.97M | $311.00M | $217.51M | $161.68M | — | -54.4% |
| Accounts receivable | $305.63M | $129.19M | $51.09M | $0 | — | +136.6% |
| Inventory | $125.59M | $110.46M | $39.82M | $0 | — | +13.7% |
| Total current assets | $630.76M | $566.36M | $317.94M | $168.27M | — | +11.4% |
| Property, plant & equipment | $6.28M | $7.15M | $8.05M | $10.82M | — | -12.2% |
| Goodwill & intangibles | — | — | $799.00K | $799.00K | $799.00K | — |
| Total assets | $1.06B | $577.69M | $329.59M | $193.57M | — | +84.1% |
| Total current liabilities | $153.76M | $90.68M | $53.72M | $53.20M | — | +69.6% |
| Current debt | — | — | — | — | $975.00K | — |
| Long-term debt | $245.65M | $244.43M | $100.12M | $71.14M | — | +0.5% |
| Total debt | $253.71M | $253.72M | $110.80M | $83.06M | — | -0.0% |
| Total liabilities | $415.23M | $355.33M | $169.09M | $134.99M | — | +16.9% |
| Retained earnings | — | — | -$1.55B | — | — | — |
| Shareholder equity | $648.02M | $222.36M | $160.50M | $58.59M | — | +191.4% |
| Working capital | $477.00M | $475.68M | $264.22M | $115.07M | — | +0.3% |
| Net tangible assets | $648.02M | $222.36M | $160.50M | $57.79M | — | +191.4% |
| Shares issued | 158.85M | 156.20M | 151.47M | 146.43M | — | +1.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $447.18M | $23.38M | $12.67M | -$223.81M | — | +1,812.4% |
| Depreciation & amortisation | $244.00K | $280.00K | $423.00K | $515.00K | — | -12.9% |
| Stock-based compensation | $64.67M | $42.54M | $37.93M | $44.66M | — | +52.0% |
| Change in working capital | -$194.54M | -$109.30M | -$84.66M | -$1.65M | — | -78.0% |
| Operating cash flow | -$24.77M | -$40.52M | -$31.41M | -$176.17M | — | +38.9% |
| Capital expenditure | -$214.00K | -$45.00K | — | -$14.00K | -$401.00K | -375.6% |
| Investing cash flow | $13.80M | -$1.04M | -$50.65M | -$20.01M | — | +1,431.9% |
| Share buybacks | -$91.24M | -$8.76M | $0 | $0 | — | -941.6% |
| Dividends paid | — | — | — | — | $0 | — |
| Financing cash flow | -$89.73M | $128.53M | $72.70M | -$391.00K | — | -169.8% |
| Free cash flow | -$24.99M | -$40.56M | -$31.41M | -$176.18M | — | +38.4% |
| End cash position | $80.49M | $181.19M | $94.22M | $103.58M | — | -55.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $240.34M | $204.92M | $192.57M | $161.71M | $141.15M | +17.3% |
| Operating revenue | $240.34M | $204.92M | $192.57M | $161.71M | $141.15M | +17.3% |
| Cost of revenue | $41.19M | $33.51M | $38.14M | $28.09M | $18.94M | +22.9% |
| Gross profit | $199.14M | $171.41M | $154.43M | $133.62M | $122.21M | +16.2% |
| Research & development | $95.34M | $48.40M | $41.19M | $40.88M | $31.78M | +97.0% |
| Selling, general & admin | $82.13M | $88.22M | $62.74M | $63.37M | $55.59M | -6.9% |
| Total operating expense | $177.47M | $136.61M | $103.94M | $104.25M | $87.37M | +29.9% |
| Operating income | $21.67M | $34.80M | $50.49M | $29.36M | $34.84M | -37.7% |
| Net interest income | -$16.57M | -$7.67M | -$6.53M | -$6.72M | -$6.72M | -116.2% |
| Pre-tax income | $10.23M | $20.36M | $45.09M | $25.91M | $30.92M | -49.7% |
| Tax provision | $2.45M | $586.00K | $22.06M | -$364.99M | $2.73M | +318.6% |
| Net income | $7.78M | $19.78M | $23.04M | $390.89M | $28.19M | -60.7% |
| Net income to common | $7.78M | $19.78M | $23.04M | $390.89M | $28.19M | -60.7% |
| Basic EPS | 0.05 | 0.14 | 0.16 | 2.69 | 0.19 | -64.3% |
| Diluted EPS | 0.05 | 0.12 | 0.14 | 2.43 | 0.17 | -58.3% |
| EBIT | $26.81M | $28.03M | $51.63M | $32.63M | $37.64M | -4.4% |
| EBITDA | $26.90M | $28.11M | $51.69M | $32.69M | $37.70M | -4.3% |
| Basic shares | 141.77M | 144.44M | 142.96M | 145.42M | 146.74M | -1.8% |
| Diluted shares | 157.28M | 160.06M | 159.37M | 161.00M | 162.56M | -1.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $482.57M | $442.21M | $79.15M | $74.08M | $129.13M | +9.1% |
| Cash & short-term investments | $552.25M | $514.43M | $141.97M | $131.58M | $251.87M | +7.4% |
| Accounts receivable | $401.56M | $392.05M | $305.63M | $265.38M | $231.52M | +2.4% |
| Inventory | $147.97M | $129.03M | $125.59M | $146.95M | $155.20M | +14.7% |
| Total current assets | $1.15B | $1.09B | $630.76M | $599.76M | $663.96M | +5.4% |
| Property, plant & equipment | $7.08M | $6.48M | $6.28M | $6.50M | $6.72M | +9.3% |
| Total assets | $1.64B | $1.53B | $1.06B | $1.03B | $702.61M | +7.2% |
| Total current liabilities | $268.49M | $187.11M | $153.76M | $156.81M | $171.89M | +43.5% |
| Long-term debt | $745.39M | $745.14M | $245.65M | $245.34M | $245.04M | +0.0% |
| Total debt | $754.44M | $753.56M | $253.71M | $253.72M | $253.72M | +0.1% |
| Total liabilities | $1.04B | $945.71M | $415.23M | $417.81M | $426.18M | +9.5% |
| Retained earnings | -$1.05B | -$1.06B | -$1.08B | -$1.11B | -$1.50B | +0.7% |
| Shareholder equity | $604.08M | $583.13M | $648.02M | $607.22M | $276.43M | +3.6% |
| Working capital | $877.19M | $899.86M | $477.00M | $442.95M | $492.07M | -2.5% |
| Net tangible assets | $604.08M | $583.13M | $648.02M | $607.22M | $276.43M | +3.6% |
| Shares issued | 153.08M | 159.97M | 158.85M | 158.75M | 158.17M | -4.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $7.78M | $19.78M | $23.04M | $390.89M | $28.19M | — | -60.7% |
| Depreciation & amortisation | $96.00K | $80.00K | $67.00K | $62.00K | $59.00K | — | +20.0% |
| Stock-based compensation | $27.88M | $19.95M | $15.65M | $17.69M | $16.36M | — | +39.7% |
| Change in working capital | $3.07M | -$69.76M | -$44.54M | -$64.71M | -$36.74M | — | +104.4% |
| Operating cash flow | $39.26M | -$17.89M | $19.66M | -$23.15M | $7.44M | — | +319.4% |
| Capital expenditure | -$293.00K | -$51.00K | -$67.00K | -$80.00K | -$42.00K | — | -474.5% |
| Investing cash flow | $1.03M | -$9.86M | -$15.64M | $46.36M | -$3.99M | — | +110.4% |
| Share buybacks | $0 | -$99.99M | $0 | -$78.24M | -$6.88M | — | +100.0% |
| Dividends paid | $0 | $0 | — | — | $0 | $0 | — |
| Financing cash flow | $85.00K | $390.83M | $1.06M | -$78.24M | -$6.44M | — | -100.0% |
| Free cash flow | $38.97M | -$17.95M | $19.59M | -$23.23M | $7.39M | — | +317.2% |
| End cash position | $483.94M | $443.56M | $80.49M | $75.41M | $130.44M | — | +9.1% |
Options analytics
Put / call volume
0.17
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
40.00
-23.4% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
+18.7%
Puts bid over calls
Call volume
927
Contracts, this expiry
Put volume
158
Contracts, this expiry
Heaviest call OI
40.00
0 contracts
Heaviest put OI
40.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.44 | 0.05 | -88.6% |
| Mar 2026 | 0.28 | 0.18 | -35.1% |
| Dec 2025 | 0.33 | 0.14 | -57.5% |
| Sep 2025 | 0.22 | 0.16 | -26.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.33 | 5 | $245.15M | +51.6% |
| Next quarter | 0.45 | 4 | $269.76M | +40.1% |
| Current year | 0.95 | 4 | $960.26M | +55.8% |
| Next year | 2.71 | 5 | $1.32B | +37.4% |
Analyst targets & ownership
Mean target$69.71
High target$86.00
Low target$21.00
Implied upside34.07%
Analyst count7
ConsensusSTRONG BUY
Strong buy / Buy1 / 6
Hold0
Sell / Strong sell0 / 1
Held by insiders7.47%
Held by institutions74.60%
Institutions holding552
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
55.31
-5.99% from price
SMA 20
55.43
-5.84% from price
SMA 50
53.59
-2.62% from price
SMA 100
51.21
+1.54% from price
SMA 200
41.54
+25.65% from price
EMA 12
54.86
-5.20% from price
EMA 26
54.93
-5.33% from price
EMA 50
53.90
-3.53% from price
RSI (14)
39.5
Neutral
MACD (12,26,9)
-0.07
Hist -0.56
ATR (14)
2.17
4.16% of price
Realised vol 30D
33.0%
Annualised
Bollinger upper
58.64
20, 2σ
Bollinger lower
52.22
20, 2σ
50 / 200 cross
Golden
53.59 vs 41.54
Trend bias
Above 200
+25.65%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.52
Less volatile than market
Correlation to SPY
0.15
Largely independent
Realised vol 30D
33.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-26.7%
Peak to trough
Max drawdown 5Y
-89.5%
Peak to trough
ATR 14
2.17
4.16% of price
Beta (reported)
1.80
5Y monthly, from filing
Short interest
Shares short
30.15M
Prior 30.11M
Change vs prior
+0.1%
Shorts adding
% of float
28.47%
Heavily shorted
% of shares out
19.70%
Against total outstanding
Days to cover
16.8
Crowded exit
Float
135.24M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 1, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 7, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Jul 27, 26 | B. Riley Securities | MAINTAINED | Buy | Buy |
| Jul 13, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 7, 26 | B of A Securities | MAINTAINED | Underperform | Underperform |
| Jul 6, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 27, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 6, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 2, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Jan 15, 26 | Goldman Sachs | MAINTAINED | Neutral | Neutral |
| Nov 3, 25 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Sep 17, 25 | B. Riley Securities | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split100:5625
Split dateApr 30, 2012
SEC filings
Periodic Financial Reports
10-Q · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-08-03
Corporate Changes & Voting Matters
8-K · 2026-06-12
Corporate Changes & Voting Matters
8-K · 2026-06-03
Corporate Changes & Voting Matters
8-K · 2026-05-27
Corporate Changes & Voting Matters
8-K · 2026-05-06
Proxy Statements
DEF 14A · 2026-04-30
Corporate Changes & Voting Matters
8-K · 2026-03-20
Headlines
Dow Jones Futures Fall After Nasdaq Hits New High; Sandisk, Micron Trigger Buy Signals
Investor's Business Daily · 14d ago
TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share
MarketBeat · 19d ago
TG Therapeutics (TGTX) Could Be 19% Undervalued After Its Recent Rebound
Simply Wall St. · 19d ago
Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?
Zacks · 20d ago
Dow Jones Futures Rise After Hawkish Fed, Warsh Hit Stocks, Trump Fumes; AMD, Bloom Energy Eye Buy Points
Investor's Business Daily · 20d ago
TG Therapeutics Makes A Bullish Move Amid Ongoing Roche Rivalry
Investor's Business Daily · 20d ago
TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · 27d ago
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
Zacks · 33d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.